Small-cell lung cancer: on the road to improved efficacy and tolerability - memoinOncology
BIO treatment regulate the translational activity of Cav-1 promoter A... | Download Scientific Diagram
CAV Regimen (Cytoxan-Adriamycin-Vincristine) | Semantic Scholar
![PDF] Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients](https://d3i71xaburhd42.cloudfront.net/f889d1ce802c5609a43181090dde16ef865f1be4/3-Table1-1.png "PDF] Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients")
PDF] Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients
ASCO 2023: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions - Megyesfalvi - 2023 - CA: A Cancer Journal for Clinicians - Wiley Online Library
PDF) Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer: CAV in refractory SCLC
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial - The Lancet Respiratory Medicine
West of Scotland Cancer Network Chemotherapy Protocol CAV for ...
Cancers | Free Full-Text | Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel
Salvage Chemotherapy with Ccnu and Methotrexate for Small Cell Lung Cancer Resistant to Cav/Pe Alternating Chemotherapy
Pilot study of cyclophosphamideâ•'doxorubicinâ•'vincristineâ•'cisplatinâ•'etoposide hybrid chemotherapy in s
Current Oncology | Free Full-Text | Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
ASCO 2023: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma | SpringerLink
Downregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil
Management of lung cancer - ScienceDirect
Chemotherapy regimens. | Download Table
A Randomized Study Comparing Cyclophosphamide, Doxorubicin, Vincristine (CAV) with Cyclophosphamide, Etoposide, Vincristine, Met
533-SCLC extensive disease CAV (CYCLOPHOSPHamide DOXOrubicin vinCRISTine) | eviQ
CAV Regimen
